Duffy antigen

Duffy antigen. The Duffy antigen, also known as the Duffy antigen/chemokine receptor (DARC), is a protein located on the surface of red blood cells and endothelial cells. It is encoded by the DARC gene on chromosome 1 and is notable for its dual role as a receptor for chemokines and as a portal for invasion by Plasmodium vivax malaria parasites. The antigen's polymorphic nature, particularly the Duffy-negative phenotype common in populations of African ancestry, has profound implications for malaria resistance and population genetics.

Structure and genetics

The Duffy antigen is a glycoprotein with seven transmembrane domains, characteristic of the G protein-coupled receptor superfamily. The encoding DARC gene is located on the long arm of chromosome 1 at position q23.2. Several alleles determine the antigen's expression on red blood cells, with the most significant being those defining the Fy(a+b-), Fy(a-b+) and Fy(a-b-) phenotypes. The Duffy-negative phenotype, Fy(a-b-), is primarily caused by a single-nucleotide polymorphism in the promoter region of the DARC gene that disrupts its expression in erythrocytes but not in other tissues like endothelial cells. This mutation is particularly associated with a TATA box variant at position -33. The FY*B allele with the -33T>C mutation is the major cause of the phenotype in individuals of West African origin.

Biological function

On endothelial cells lining postcapillary venules, the Duffy antigen functions as a scavenger receptor for a wide range of inflammatory chemokines, including CXCL1 and CXCL8 (also known as IL-8). This activity helps to regulate local concentrations of these signaling proteins during inflammation. Its presence on red blood cells, which vastly outnumber leukocytes, provides a large circulating sink for chemokines, potentially modulating the immune response. The receptor binds chemokines from both the CXC chemokine and CC chemokine families, a promiscuity unusual among chemokine receptors. This interaction is independent of G protein signaling, classifying it as a silent or atypical receptor.

Clinical significance

The Duffy antigen is critically important in malaria epidemiology. Plasmodium vivax and the related simian malaria parasite Plasmodium knowlesi require interaction with this antigen to invade red blood cells. Consequently, individuals with the Duffy-negative phenotype (Fy(a-b-)) on their erythrocytes are highly resistant to infection by Plasmodium vivax. This has made the Duffy-negative genotype a powerful evolutionary selective pressure in malaria-endemic regions. In transfusion medicine, the antigen is one of the significant minor blood group systems; antibodies against Fy^a or Fy^b antigens can cause hemolytic transfusion reactions and hemolytic disease of the newborn. Furthermore, studies have investigated its role in moderating HIV infection progression and influencing metastasis in certain cancers, such as prostate cancer and breast cancer.

Distribution and population genetics

The geographic distribution of Duffy alleles is highly stratified. The Duffy-negative phenotype is nearly fixed in populations indigenous to Sub-Saharan Africa, with prevalence exceeding 95% in many regions of West Africa and Central Africa. This distribution closely mirrors the historical endemicity of Plasmodium vivax malaria. In contrast, the phenotype is rare among populations of European, Asian, and Native American ancestry, where the Fy(a+b-) or Fy(a-b+) phenotypes predominate. This stark genetic differentiation makes the DARC gene a classic example of positive selection in human evolution. The pattern is so distinct that it has been used in population genetics studies to trace human migration and admixture, such as the Atlantic slave trade.

History and discovery

The antigen was first identified in 1950 through the serum of a hemophiliac patient named Mr. Duffy, who had undergone multiple blood transfusions and developed an antibody. This discovery was made by researchers at the Blood Group Reference Laboratory in London. The antibody defined a new blood group system, initially named the Duffy system. Its critical role in malaria was uncovered decades later when researchers, including Louis H. Miller of the National Institutes of Health, demonstrated in the 1970s that Plasmodium knowlesi merozoites required the Duffy antigen to invade human red blood cells. This finding was later extended to Plasmodium vivax. The molecular cloning of the DARC gene in the 1990s confirmed its identity as a promiscuous chemokine receptor, elucidating its dual physiological and pathological functions. Category:Blood group antigens Category:Malaria Category:Proteins Category:Human genetics